1104 – Pharmacogenomics

!DOCTYPE HTML>

Formulary Management


Pharmacogenomics (1104)


Source: Council on Therapeutics


To advocate that pharmacists take a leadership role in the therapeutic applications of pharmacogenomics, which is essential to individualized drug therapy; further,


To support research to validate and standardize genetic markers and genetic testing for drug therapy and to support research and other efforts that guide and accelerate the application of pharmacogenomics to clinical practice; further,


To advocate for the inclusion of pharmacogenomic test results in medical and pharmacy records in a format that clearly states the implications of the results for drug therapy and facilitates availability of the genetic information throughout the continuum of care and over a patient’s lifetime; further,


To encourage pharmacists to educate prescribers and patients about the use of pharmacogenomic tests and their appropriate application to drug therapy management; further,


To encourage pharmacist education on the use of pharmacogenomics and advocate for the inclusion of pharmacogenomics and its application to therapeutic decision-making in college of pharmacy curricula.


This policy supersedes ASHP policy 0016.


Medications Derived from Biologic Sources (0809)


Source: Council on Pharmacy Practice


To encourage pharmacists to take a leadership role in their health systems for all aspects of the proper use of medications derived from biologic sources, including preparation, storage, control, distribution, administration procedures, safe handling, and therapeutic applications; further,


To facilitate education of pharmacists about the proper use of medications derived from biologic sources.


(Note: Section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] defines biological product as follows: a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, or arsphenamine or derivative of arsphenamine [or any other trivalent organic arsenic compound], applicable to the prevention, treatment, or cure of a disease or condition of human beings.)


This policy was reviewed in 2012 by the Council on Pharmacy Practice and by the Board of Directors and was found to still be appropriate.


Generic Substitution of Narrow Therapeutic Index Drugs (0817)


Source: Council on Therapeutics

Only gold members can continue reading. Log In or Register to continue

Aug 27, 2016 | Posted by in GENERAL & FAMILY MEDICINE | Comments Off on 1104 – Pharmacogenomics
Premium Wordpress Themes by UFO Themes
%d bloggers like this: